KyungDong Pharm home
Prescription Medicines

Inhipla Tab.

Product Category
antiplatelet drugs
Active Ingredients
clopidogrel sulfate
Appearance
Pink round film-coated tablets
Reimbursement Code
648101690
View Regulatory Information on the MFDS Portal ↗
1. Composition and Strength : 1 tablet
- Active ingredient: Clopidogrel sulfate (USP) ---------- 97.875mg (75mg as clopidogrel)
- Additives (tar color aluminum lake): Red No. 40, Yellow No. 5
- Other additives: Microcrystalline cellulose, Opadry pink (03B44038), silicon dioxide, low-substituted hydroxypropyl cellulose, talc, polyethylene glycol 6000, castor lead,
D-mannitol

2. Efficacy/Effectiveness
1. Improvement of atherosclerotic symptoms in adult patients with ischemic stroke, myocardial infarction, or peripheral arterial disease
2. Acute coronary syndrome [drug treatment or coronary intervention (PCI) (with or without stent surgery) in patients with unstable angina or non-Q wave myocardial infarction, and
In adult patients with atherosclerotic symptoms (including those who have undergone or will undergo coronary artery bypass grafting (CABG)), atherosclerotic symptoms (death from cardiovascular events, myocardial infarction, stroke)
or refractory ischemia)
3. In adult patients with atrial fibrillation who have one or more vascular risk factors, are not suitable for vitamin K antagonist (VKA) administration, and have a low risk of bleeding, including stroke.
Reduced risk of atherothrombosis and thromboembolism

3. Usage/Dosage
○ Adult
1. For patients with ischemic stroke, myocardial infarction, or peripheral arterial disease, 75 mg of clopidogrel is administered orally once a day.
2. For patients with acute coronary syndrome (unstable angina or non-Q wave myocardial infarction), take 300 mg once a day as a loading dose on the day of starting this drug.
After starting, administer 75 mg orally once a day as a maintenance dose. At this time, 75 to 325 mg of aspirin should be administered together with this drug once a day.
3. For patients with atrial fibrillation, 75 mg of this drug is administered orally once a day. At this time, 75 to 100 mg of aspirin should be administered together with this drug once a day.
○ Patients with renal impairment: Treatment experience in patients with renal impairment is limited.
○ Patients with liver disease: Treatment experience is limited in patients with moderate liver disease with a bleeding diathesis.

This drug can be administered regardless of food intake.

4. Precautions for use
1. Warning
1) Patients with genetically reduced function of CYP2C19: Compared to patients with normal CYP2C19 function, patients with genetically reduced function of CYP2C19 have less systemic exposure to the active metabolite of this drug, resulting in decreased antiplatelet response. In general, there is a higher probability of cardiovascular events occurring after myocardial infarction. Therefore, if a patient is identified as having reduced function of CYP2C19, treatment or alternative treatment should be considered.
2) Use of drugs that induce the activity of CYP2C19 may increase the drug concentration of the active metabolite of this drug and increase the risk of bleeding. Co-administration of this drug with CYP2C19 inducers is not recommended.

2. Do not administer to the following patients.
1) Patients with hypersensitivity to this drug or its components
2) Patients with bleeding (peptic ulcer, intracranial hemorrhage, hemophilia, digestive tract bleeding, urinary tract bleeding, hemoptysis, vitreous hemorrhage, etc.)
3) Patients with severe liver damage
4) Nursing mothers

3. Administer with caution to the following patients.
1) Because there is a risk of bleeding and hemorrhagic adverse reactions, a blood count or other appropriate test should be considered promptly whenever these clinical symptoms are suspected during treatment. Caution should be exercised when administering this drug and warfarin together as the risk of bleeding increases. This drug prolongs bleeding time, so it should be administered with caution to patients with lesions that may cause bleeding (especially gastrointestinal and intraocular lesions). Additionally, like other antiplatelet agents, this drug should be administered cautiously to patients at increased risk of bleeding due to trauma, surgery, or other pathological conditions (e.g., congenital or acquired coagulation abnormalities, thrombocytopenia or functional platelet defects, active ulcerative gastrointestinal disease, recent biopsy, bacterial endocarditis, etc.). If a patient is scheduled to undergo surgery and the antiplatelet effect is undesirable, administration of this drug should be discontinued 5 to 7 days before surgery. Resume administration of this drug as soon as hemostasis is achieved. Patients taking this drug should be cautious when using it in combination with drugs that may cause gastrointestinal lesions (aspirin and other non-steroidal anti-inflammatory drugs (NSAIDs)), heparin, glycoprotein IIb/IIIa inhibitors, selective serotonin reuptake inhibitors (SSRIs), thrombolytics, drugs with a risk of bleeding such as pentoxifylline, or CYP2C19 inducers. In particular, patients should be carefully observed for any bleeding symptoms, including occult bleeding, during the first week of administration and/or following invasive cardiac procedures or surgery.
In patients with a transient ischemic attack or stroke who are at high risk of recurrent ischemic events, combining this medicine with aspirin has been shown to increase major bleeding. Combination therapy should therefore be considered carefully in these patients only when its benefits are clearly established (see section 6, Interactions).
For patients with acute non-cardiogenic ischemic stroke or transient ischemic attack, triple antiplatelet therapy (clopidogrel + aspirin + dipyridamole) for secondary prevention of stroke is not recommended due to the increased risk of bleeding (see Section 6. Interactions).
2) Patients with liver disease
There is limited experience with the use of this drug in patients with severe liver disease and a predisposition to bleeding. This drug should be administered with caution to these patients.
3) Patients with renal impairment
Because experience with the use of this drug in patients with severe renal impairment is limited, this drug should be administered cautiously to these patients.
4) Acute stroke patients (within 7 days) (Administration is not recommended due to lack of relevant data.)
5) Patients taking CYP2C19 inhibitors (see section 6. Interactions)
6) Patients with persistent high blood pressure
7) Elderly people
8) Underweight patients
9) Cross-sensitivity reaction with thienopyridine drugs
Since cross-hypersensitivity reactions with this drug have been reported with thienopyridine drugs (e.g., ticlopidine, prasugrel), the patient's history of hypersensitivity to other thienopyridine drugs should be reviewed. Thienopyridine drugs can cause mild to severe allergic reactions such as rash and angioedema, or hematological reactions such as thrombocytopenia and neutropenia. Patients who have previously had an allergic and/or hematological reaction to one thienopyridine drug may be at increased risk of having the same or different reaction to another thienopyridine drug. Monitoring for cross-sensitivity reactions is recommended.
10) Acquired hemophilia
There have been reported cases of acquired hemophilia after using this drug. If prolonged activated partial thromboplastin time (aPTT), with or without bleeding, is confirmed, acquired hemophilia should be investigated. Patients diagnosed with acquired hemophilia should discontinue treatment and receive treatment from a specialist.
11) This drug contains Yellow No. 5 (Sunset Yellow FCF), so administer with caution to patients who are hypersensitive to this ingredient or have a history of allergy.

4. Adverse reactions
The safety of this drug was evaluated in more than 44,000 patients, including 12,000 who took this drug for more than one year. The overall tolerability of this drug was similar to that of aspirin, regardless of age, gender, and race. Patients who discontinued treatment due to adverse reactions occurred at approximately the same frequency as aspirin (13%). Clinically important adverse reactions observed in the CAPRIE, CURE, CLARITY, COMMIT, ACTIVE-A, and ACTIVE-W studies are as follows.
1) Bleeding disorder
- In the CAPRIE study, the overall incidence of bleeding was the same in the Aspirin and Aspirin groups (9.3%), and the incidence of severe bleeding was 1.4% in the Aspirin group and 1.6% in the Aspirin group, respectively.
Specifically, the overall gastrointestinal bleeding rate was 2.0% in the drug-treated group, of which 0.7% required hospitalization. On the other hand, in the patient group administered aspirin, the gastrointestinal bleeding rate was 2.7% and hospitalization was required in 1.1%. In addition, the incidence of other bleeding was 7.3% in the group administered this drug, which was higher than that of aspirin (6.5%). However, the incidence of severe bleeding was similar in the two treatment groups (0.6% vs. 0.4%). In addition, purpura/bruising/haematoma and epistaxis occurred most frequently, while hematoma, hematuria, and intraocular hemorrhage (mainly in the conjunctival region) were reported less frequently. The intracranial hemorrhage rate was 0.5% with aspirin and 0.4% with this drug.
- In the CURE study, there was an increase in major and minor bleeding in the group of patients receiving aspirin in combination with this medicine compared to the group of patients receiving placebo and aspirin (incidence of major bleeding, 2.7% vs. 3.7%, incidence of minor bleeding, 2.4% vs. 5.1%). The locations where major bleeding usually occurred were the gastrointestinal system and puncture sites. There was a statistically non-significant increase in the incidence of life-threatening bleeding in patients receiving aspirin plus placebo compared with patients receiving placebo and aspirin (1.8% vs. 2.2%). There was no difference in the incidence of fatal bleeding between the two treatment groups (0.2% in both groups). The incidence of major, non-life-threatening bleeding was significantly higher in the group treated with this drug and aspirin than in the placebo and aspirin group (1.0% vs. 1.6%), and the rate of intracranial hemorrhage in the two treatment groups was the same at 0.1%.
- In the CURE study, the bleeding rate in the group administered this drug and aspirin together is as shown in the table below (% of patients). (Refer to the table attached)

* Other appropriate standard therapies were used during treatment.
**(a) The incidence of major bleeding symptoms with clopidogrel + aspirin was dose-proportional to aspirin (<100 mg = 2.6%; 100 to 200 mg = 3.5%; >200 mg = 4.9%).
**(b) The incidence of major bleeding symptoms with placebo + aspirin was dose proportional to aspirin (<100 mg = 2.0%; 100 to 200 mg = 2.3%; >200 mg = 4.0%).
*** Because of this, administration of the drug was stopped.

- In the CURE study, 92% of patients received heparin and low-molecular-weight heparin, and the bleeding rate in these patients was similar to the overall results of this drug. In patients who stopped taking this drug at least 5 days before surgery, no additional major bleeding was observed within 7 days after coronary artery shunt surgery (4.4% in the drug and aspirin group, 5.3% in the placebo and aspirin group).
In patients who received this drug within 5 days prior to coronary artery shunt surgery, the incidence of hemorrhagic symptoms was 9.6% in the drug and aspirin group and 6.3% in the placebo and aspirin group.

- In the CLARITY study, the incidence of major bleeding (intracranial hemorrhage or bleeding associated with a decrease in hemoglobin of more than 5 g/dL) was similar in the two treatment groups (1.3% vs 1.1% in the drug + aspirin and placebo + aspirin groups, respectively). This was consistent across patient subgroups according to baseline characteristics and type of fibrinolytic agent or heparin therapy. The incidence of fatal hemorrhage (0.8% vs 0.6% in the aspirin plus placebo group and placebo + aspirin group, respectively) and intracranial hemorrhage (0.5% vs 0.7%, respectively) were low and similar in the two groups.

- In the COMMIT study, major bleeding other than the brain or bleeding in the brain was low and similar in the two groups, as shown in the table above. The number (%) of patients who experienced bleeding in the COMMIT study is as follows. (See table-attached document)

* Major bleeding refers to bleeding in the brain or other than the brain, leading to death or requiring a blood transfusion.
** The correlation rate of major extracerebral or intracerebral hemorrhage was independent of age. The incidence rate of this drug + aspirin group according to age was less than 60 years old = 0.3%, 60 to 70 years old = 0.7%, and 70 years old or older = 0.8%. In the placebo + aspirin group, those under 60 years old = 0.4%, those between 60 and 70 years old = 0.6%, and those over 70 years old = 0.7%.

- In the ACTIVE-A study, the incidence of major bleeding in the group treated with this drug and aspirin was higher than in the group treated with placebo and aspirin (6.7% vs. 4.3%), and major bleeding was mostly extracranial (5.3% vs. 3.5%) and mainly gastrointestinal bleeding (3.5% vs. 1.8%). The incidence of intracranial hemorrhage was higher in patients treated with aspirin and aspirin (1.4% vs. 0.8%). The incidence of fatal bleeding and hemorrhagic stroke did not show a statistically significant difference between the two groups (fatal bleeding: 1.1% vs. 0.7%, hemorrhagic stroke: 0.8% vs. 0.6%). (See table-attached document)

a: adjudicated case
b: Includes 1 patient who was not bleeding but was judged to have a hemorrhagic stroke
c: Incidence rate of major bleeding according to age in the clopidogrel + aspirin group: under 65 years = 3.3%, 65 to 75 years = 7.1%, over 75 years = 8.3%; Incidence rate of major bleeding according to age in the aspirin only group: under 65 years = 1.9%, 65 to 75 years = 3.9%, over 75 years = 6.0%.
*: Intracranial hemorrhage, including hemorrhagic stroke and subdural hematoma.

- In the ACTIVE-W study, there was no significant difference in the incidence of major bleeding between the group treated with this drug and aspirin and the group treated with oral anticoagulants. Fatal bleeding was reported less frequently in both groups (0.21% vs. 0.33%). The total incidence of bleeding was significantly higher in the group administered this drug and aspirin together than in the oral anticoagulant group (see table-attached document).

a: adjudicated case
b: Includes 1 patient who was not bleeding but was judged to have a hemorrhagic stroke

The ACTIVE-A study and the ACTIVE-W study were individual studies within the ACTIVE program, targeting patients with atrial fibrillation who had one or more risk factors for vascular events. Among these patients, based on the subject registration criteria, patients suitable to receive vitamin K antagonists (warfarin, etc.) were assigned to the ACTIVE-W study, and patients not suitable to receive vitamin K antagonists (if the patient could not receive vitamin K antagonists or did not want to receive vitamin K antagonists) were assigned to the ACTIVE-A study.
The results of the ACTIVE-W study showed that vitamin K antagonists were more effective than the group administered in combination with this drug and aspirin.
2) Hematological disorders (neutropenia/agranulocytosis, etc.)
- In the CAPRIE study, severe neutropenia (<0.450G/L) occurred in 6 cases, including 4 cases (0.04%) in the Aspirin group and 2 cases (0.02%) in the aspirin group.
Among the 9,599 patients administered this drug, two had neutrophil counts of 0, but these symptoms did not appear in the 9,586 patients administered aspirin. Of the four patients in the treatment group, one was receiving cytotoxic chemotherapy, and the other patient recovered after temporary discontinuation of the drug and returned to the clinical trial.
※ The incidence of severe neutropenia caused by ticlopidine, which is chemically similar to this drug, was 0.8% (<0.450G/L).
Aplastic anemia occurred in one case in the group receiving this drug. The incidence of severe thrombocytopenia (<80G/L) was 0.2% in the drug-treated group and 0.1% in the aspirin-treated group, and cases of platelet counts falling below 30G/L were very rarely reported.
- In the CURE study, the incidence of thrombocytopenia was similar at 19 patients in the drug and aspirin group, 24 patients in the placebo and aspirin group, and the incidence of agranulocytosis was 3 patients each.
Although the risk of myelotoxicity with this drug is fairly low, the possibility of myelotoxicity should be considered if a patient receiving this drug develops fever or other symptoms of infection.
3) Gastrointestinal symptoms
In the CAPRIE study, the overall incidence of gastrointestinal symptoms (e.g., abdominal pain, dyspepsia, gastroenteritis, or constipation) was 27.1% in patients taking this drug compared with 29.8% in patients taking aspirin. In the CURE study, the incidence of gastrointestinal symptoms was 11.7% in the drug and aspirin group and 12.5% ​​in the placebo and aspirin group.
- In the CAPRIE study, the incidence of peptic (stomach or duodenal) ulcers was 0.7% in the drug-treated group and 1.2% in the aspirin-treated group. In the CURE study, the incidence of peptic (stomach or duodenal) ulcers was 0.4% in the drug and aspirin group and 0.3% in the placebo and aspirin group.
- In the CAPRIE study, diarrhea was reported in 4.5% of patients in the aspirin group compared to 3.4% in the aspirin group. However, serious cases rarely occurred (0.2% in the drug-treated group and 0.1% in the aspirin-treated group). According to the CURE study, diarrhea occurred in 2.1% of patients receiving this drug and aspirin, and 2.2% of patients receiving placebo and aspirin.
- In the CAPRIE study, the frequency of patients discontinuing treatment due to gastrointestinal adverse reactions was 3.2% in the drug-treated group and 4.0% in the aspirin-treated group. According to the CURE study, the frequency of patients discontinuing treatment due to gastrointestinal adverse reactions was 0.8% in the placebo and aspirin group, compared to 0.9% in the drug and aspirin group.
4) Rashes and other skin diseases
- In the CAPRIE study, the incidence of adverse reactions in the skin and skin appendages in the patient group administered this drug was 15.8% (severe adverse reaction 0.7%), and in the patient group administered aspirin it was 13.1% (severe adverse reaction 0.5%). In the CURE study, the incidence of abnormalities in the skin and skin appendages was 4.0% in the drug and aspirin group and 3.5% in the placebo and aspirin group.
- In the CAPRIE study, the overall incidence of patients discontinuing treatment with this drug due to adverse reactions to the skin and skin appendages was 1.5%, whereas it was 0.8% in the aspirin group. According to the CURE study, the incidence of patients discontinuing treatment due to adverse reactions to the skin and skin appendages was 0.7% in the drug and aspirin group and 0.3% in the placebo and aspirin group.
5) In clinical studies of CAPRIE, adverse reactions with an occurrence rate of 2.5% or more in the patient group receiving this drug, regardless of their relationship to this drug, were listed in the table below. The average treatment period was 20 months, and the longest treatment period was 3 years.

* In the CAPRIE study, adverse reactions occurred in more than 2.5% of patients administered this drug (see table-attached document)

6) In the CURE study, adverse reactions with an occurrence rate of 2.0% or more in the patient group receiving this drug, regardless of their relationship to this drug, are listed in the table below.

* In the CURE study, adverse reactions occurred in more than 2.0% of patients administered this drug (see table-attached document)

* Other appropriate standard therapies were used during treatment.

7) In addition, in the CAPRIE or CURE studies, important adverse reactions that were likely to occur in 1 to 2.5% of patients unrelated to administration of this drug are as follows. In general, the frequency of these symptoms was similar in those receiving aspirin (in the CAPRIE study) or placebo and aspirin (in the CURE study).
(1) Autonomic nervous system: fainting, palpitations
(2) Whole body: Asthenia, fever, hernia
(3) Cardiovascular system: heart failure, atrial fibrillation
(4) Central and peripheral nervous system: leg cramps, hypoesthesia, neuralgia, paresthesia, dizziness
(5) Digestive system: constipation, vomiting
(6) Hepatobiliary system: increase in liver enzymes
(7) Metabolism and nutrition: gout, hyperuricemia, increase in non-protein nitrogen (NPN)
(8) Musculoskeletal system: Arthritis. arthrosis
(9) Mental system: anxiety, insomnia
(10) Blood and lymphatic system: anemia, gastrointestinal bleeding, hematoma, thrombocytopenia
(11) Respiratory system: pneumonia, sinusitis
(12) Skin and skin appendages: eczema, skin ulcers
(13) Urinary system: cystitis
(14) Eyes: cataracts, conjunctivitis
8) In the CAPRIE or CURE studies, serious adverse reactions that were rarely reported (less than 1%) but were clinically important and likely to occur unrelated to the administration of this drug are as follows. In general, the frequency of these symptoms was similar in the aspirin group (in the CAPRIE study) or placebo plus aspirin group (in the CURE study).
(1) Whole body: allergic symptoms, ischemic necrosis
(2) Cardiovascular system: Whole body edema
(3) Digestive system: gastritis, hemorrhagic gastroenteritis, duodenal ulcer, gastric ulcer, perforated gastric ulcer, upper gastrointestinal ulcer bleeding, flatulence
(4) Hepatobiliary system: bilirubinemia, infectious hepatitis, fatty liver
(5) Platelet, bleeding and coagulation diseases: hemorrhagic arthrosis, hematuria, hemoptysis, intracranial hemorrhage, retroperitoneal hemorrhage, surgical wound hemorrhage, eye hemorrhage, pulmonary hemorrhage, purpura allergy, thrombocytopenia, increased bleeding time.
(6) Blood and lymphatic system: aplastic anemia, hemoglobinopenic anemia, agranulocytosis, granulocytopenia, leukemia, leukopenia, neutropenia, eosinophilia
(7) Reproductive system: excessive menstruation
(8) Respiratory system: hemothorax
(9) Skin and skin appendages: herpes macrophages, erythematosus rash, maculopapularis, urticaria
(10) Urinary system: abnormal renal function, acute renal failure
9) Adverse reactions reported through post-marketing use in foreign countries were classified by site of occurrence. (frequency unclear)
(1) Blood and lymphatic system:
① Severe bleeding: Mainly skin (purpura), musculoskeletal system (hemorrhagic arthrosis, hematoma), eye (conjunctiva, intraocular, retinal area) and airway area (hemoptysis, pulmonary hemorrhage), epistaxis, hematuria, and bleeding from surgical wounds.
② Fatal bleeding (especially intracranial, gastrointestinal, and retroperitoneal space bleeding)
Agranulocytosis, aplastic anemia/pancytopenia and thrombotic thrombocytopenic purpura (TTP) (1/200,000 exposed patients), severe thrombocytopenia (platelet count ≤30 x 109/L), acquired hemophilia A
(2) Immune system: Anaphylactoid reactions, serum sickness, cross-hypersensitivity reactions with thienopyridine drugs (e.g. ticlopidine, prasugrel), insulin autoimmune syndrome (severe hypoglycemia may occur in patients with HLADRA4 subtype. Occurs more frequently in Japanese people)
(3) Mental world: confusion, hallucinations
(4) Nervous system: dysgeusia, loss of taste
(5) Vascular system: vasculitis, hypotension
(6) Respiratory system: bronchospasm, interstitial pneumonia, eosinophilic pneumonia
(7) Digestive system: colitis (including ulcerative colitis or lymphocytic colitis), pancreatitis, gastritis, stomatitis
(8) Hepatobiliary system: hepatitis, acute liver failure
(9) Skin and subcutaneous tissue: maculopapular erythematous or exfoliative skin rash, urticaria, itching, angioedema, bullous dermatitis (erythema multiforme, mucocutaneous ocular syndrome (Stevens-Johnson syndrome), toxic epidermal necrolysis (Riel syndrome), acute systemic exanthematous pustulosis (AGEP), etc.), drug-induced hypersensitivity syndrome, eosinophilia and systemic symptoms. Drug rash (DRESS), eczema, lichen planus
(10) Musculoskeletal system: joint pain, arthritis, muscle pain
(11) Kidney and urinary system: glomerulopathy
(12) Reproductive system and breast diseases: Gynecomastia
(13) Whole body and administration site: fever
(14) Abnormal test values: abnormal liver function levels, increased blood creatinine
10) Domestic post-marketing survey results
(1) As a result of a post-marketing survey conducted on 4,295 people over 6 years for re-examination in Korea, the case rate of adverse reactions was reported to be 9.78% (420 cases/4,295 cases) regardless of causal relationship, and of these, 6.50% (279 cases/4,295 cases) were found to have a causal relationship with this drug. Dizziness was the most common at 1.19% (51 cases), followed by indigestion at 1.12% (48 cases), and headache at 1.07% (46 cases).
(2) Other adverse reactions reported in less than 1% are as follows.
① Central and peripheral nervous system: Dyskinesia, tremor, voice disorder, abnormal gait, hyperkinesia, ataxia, paresthesia
② Digestive system: constipation, nausea, diarrhea, ulcer, abdominal pain, loss of appetite, vomiting, hiccups, dry mouth, dysphagia, tongue disease
③ Mental nervous system: insomnia, depression, forgetfulness, anxiety, somnolence, abnormal thinking, abnormal behavior
④ Skeletal muscular system: joint pain, muscle pain, back pain, arthrosis
⑤ Whole body: chest pain, weight loss, weight gain, facial flushing, fatigue, weakness, stiffness, facial edema, fainting
⑥ Blood system: purpura, hematochezia, epistaxis, hemorrhage, cerebral hemorrhage, hematoma, hematuria, hemoptysis, muscle hemorrhage, intracranial hemorrhage, eye hemorrhage, gingival hemorrhage, thrombocytopenia, anemia
⑦ Respiratory system: cough, difficulty breathing, rhinitis
⑧ Sense organs: visual abnormalities, visual field disturbances, dry eyes, temporary blindness, bloodshot eyes, tinnitus, loss of taste
⑨ Urinary tract: urinary dysfunction, frequent urination, increased non-protein nitrogen, uremia, increased blood urea nitrogen.
⑩ Metabolism and nutrition: hypoglycemia, hyperuricemia
⑪ Hepatobiliary system: increased liver enzymes, increased ALT, abnormal liver function
⑫ Cardiovascular system: leg edema, arrhythmia, bradycardia, palpitations
⑬ Skin and appendages (including administration site): rash, itching, contact dermatitis
⑭ Reproductive system: Gynecomastia, elevated prostate-specific antigen (PSA)
(3) Among the new adverse reactions that did not appear in pre-marketing clinical trials, a causal relationship with the drug cannot be ruled out: anorexia, weight loss in 7 cases, visual abnormalities in 4 cases, somnolence, weight gain, and facial flushing in 3 cases, hypokinesia, dry mouth, forgetfulness, abnormal thinking, frequent urination, arrhythmia in 2 cases each, tremor, voice disorder, abnormal gait, hyperkinesis, ataxia, hiccups, dysphagia, One case each of tongue disease, abnormal behavior, stiffness, visual disturbance, dry eyes, temporary blindness, congestion, urination disorder, uremia, hypoglycemia, bradycardia, tinnitus, contact dermatitis, gynecomastia, and elevated PSA was reported.
11) As a result of analysis and evaluation of clue information based on domestic post-marketing adverse event reporting data (1989-2015), the newly confirmed adverse cases are as follows. However, this does not mean that the causal relationship between the relevant ingredient and the following adverse events has been proven.
⦁ Digestive system: cholecystitis, hematemesis
⦁ Blood and lymphatic system: spinal hematoma

5. General precautions
1) Clopidogrel is a prodrug. Since the inhibition of clopidogrel platelet aggregation is due to the active metabolite of clopidogrel, the metabolism of clopidogrel to the active metabolite may be impaired due to genetic variation in CYP2C19 or concomitant use with drugs that interfere with CYP2C19.
2) Inform patients that it may take longer than usual to stop bleeding when administering this drug alone or in combination with aspirin, and instruct them to immediately report to a doctor if bleeding abnormalities (bleeding area or duration) occur. Patients should tell their doctors and dentists that they are taking this medication before planning surgery or taking any new medications.
3) Thrombotic thrombocytopenic purpura (TTP): TTP has been rarely reported after using this drug, and sometimes even after short-term use (within 2 weeks). TTP is a serious, potentially fatal condition that requires immediate treatment such as plasmapheresis (plasmapheresis) and is characterized by thrombocytopenia, microvascular hemolytic anemia (split red blood cells observed in microsmear specimens), neurological findings, renal failure, and fever. In clinical trials, TTP did not occur in more than 17,500 patients receiving this drug, but in post-marketing use worldwide, it has been reported at a rate of approximately 4 cases per million patients who have ever received this drug, or approximately 11 cases per million person-years. Meanwhile, the baseline incidence of this disease (TTP) is estimated to be approximately 4 cases per million person-years.
4) Based on biological potential, if rapid conversion is necessary, platelet transfusion can be performed to reverse the pharmacological effects of this drug.
5) Because there is a risk of bleeding and hematological adverse reactions, if clinical symptoms suspected of such adverse reactions appear during treatment, blood cell count determination or other appropriate tests should be immediately considered.
6) It was observed that the administration of this drug did not affect the patient's driving function or psychological function.

6. Interaction
1) Drugs associated with the risk of bleeding: Caution should be exercised when administering drugs associated with the risk of bleeding in combination with this drug, as the risk of bleeding may increase due to potential additive effects. (Refer to section 3. Administration with caution to the following patients).
2) Glycoprotein IIb/IIIa inhibitors: There may be pharmacodynamic interactions between this drug and glycoprotein IIb/IIIa inhibitors, so caution should be exercised during co-administration.
3) Aspirin: There may be pharmacodynamic interaction between this drug and aspirin, so caution should be exercised when co-administered. Aspirin did not alter the inhibitory effect of aspirin on ADP-induced platelet aggregation, but it enhanced the effect of aspirin on collagen-induced platelet aggregation. However, when 500 mg of aspirin was administered twice daily with this drug for 1 day, the prolongation of bleeding time was not significantly increased by this drug. There are cases where this drug and aspirin (75 to 325 mg once daily) were administered together for up to one year.
4) Non-steroidal anti-inflammatory drugs (NSAIDs): In clinical trials on healthy volunteers, co-administration of this drug and naproxen increased potential gastrointestinal bleeding. However, there are no studies on the co-administration of this drug with other NSAIDs, so it is currently unclear whether all NSAIDs increase the risk of gastrointestinal bleeding. Therefore, this drug and non-steroidal anti-inflammatory drugs (NSAIDs), including Cox-2 inhibitors, should be administered together with caution.
5) Thrombolytics: The safety of coadministering this drug with rt-PA and heparin was evaluated in patients who had recently experienced myocardial infarction. At this time, the incidence of clinically significant bleeding was similar to that observed when aspirin was administered in combination with rt-PA and heparin.
6) Injectable anticoagulants: In a study on healthy volunteers, this drug did not change the effect of heparin on coagulation and did not require adjustment of the heparin dose. Co-administration of heparin did not affect the inhibitory effect of this drug on platelet aggregation. However, as the risk of bleeding may increase due to pharmacodynamic interaction between this drug and heparin, caution should be exercised during co-administration.
7) Oral anticoagulants: Do not use this drug together with oral anticoagulants because it may increase the intensity of bleeding.
8) Selective serotonin reuptake inhibitors (SSRI): Selective serotonin reuptake inhibitors affect platelet activity and increase the risk of bleeding, so this drug and selective serotonin reuptake inhibitors should be administered with caution when administered together.
9) Morphine and other opioids: Delays and decreases in exposure to clopidogrel and its metabolites have been observed when co-administering this drug and morphine in healthy volunteers. This interaction may be due to decreased gastrointestinal motility and may also apply to other opioid agonists. The clinical relevance is unknown, but as with other oral P2Y12 inhibitors, the efficacy of this drug may be reduced in patients receiving this drug concurrently with morphine. The use of parenteral antiplatelet agents should be considered in patients with acute coronary syndromes who require concomitant use of morphine or other opioid agonists.
10) Other combination treatments
(1) CYP2C19 inducer: This drug is partially metabolized to active metabolites through CYP2C19. Co-administration with drugs that induce CYP2C19 activity may increase the concentration of this drug's active metabolite, and therefore, the risk of bleeding may increase when this drug is co-administered with rifampicin, a CYP2C19 inducer. Coadministration of this drug with CYP2C19 inducers is not recommended.
(2) CYP2C19 inhibitor: Since this drug is partially metabolized into active metabolites through CYP2C19, the drug concentration of the active metabolite of this drug may be lowered when co-administered with drugs that inhibit the activity of CYP2C19. The clinical relevance of this interaction is unclear. Coadministration of this drug with CYP2C19 inhibitors is not recommended (CYP2C19 inhibitors e.g. omeprazole, esomeprazole, fluvoxamine, fluoxetine, moclobemide, voriconazole, fluconazole, ticlopidine, ciprofloxacin, cimetidine, carbamazepine, oxcarbazepine, chloramphenicol, etc.).
(3) When 80 mg of omeprazole once daily was administered with this drug simultaneously or 12 hours apart, exposure to the active metabolite was reduced by 45% (loading dose) and 40% (maintenance dose). This reduction was associated with a 39% (loading dose) and 21% (maintenance dose) reduction in platelet aggregation inhibition. Esomeprazole is also expected to have a similar interaction with this drug.
A somewhat lower reduction in metabolite exposure was observed with pantoprazole or lansoprazole.
During combined treatment with 80 mg of pantoprazole once daily, the blood concentration of the active metabolite was reduced by 20% (loading dose) and 14% (maintenance dose). This reduction was associated with a 15% (loading dose) and 11% (maintenance dose) reduction in mean platelet aggregation inhibition.
(4) Many clinical studies have been conducted to investigate the pharmacodynamic and pharmacokinetic interactions caused by co-administration of this drug with other drugs. No clinically significant pharmacodynamic interactions were observed when this drug was administered simultaneously with atenolol, nifedipine, or both atenolol and nifedipine. Additionally, the pharmacodynamics of this drug were not significantly affected by co-administration of phenobarbital or estrogens. The pharmacokinetics of digoxin or theophylline were not altered by co-administration of these drugs. The degree of absorption of this drug was not changed by antacid administration.
(5) In patients receiving long-term warfarin treatment, coadministration of 75 mg of clopidogrel did not affect the pharmacokinetic pattern or INR of S-warfarin, which is a substrate of CYP2C9, but it has an independent effect on hemostasis, so the combined use of this drug and warfarin increases the risk of bleeding. However, in vitro, high-dose clopidogrel inhibits CYP2C9 activity.
Results from the CAPRIE study showed that this drug can be safely co-administered with phenytoin or tolbutamide.
(6) CYP2C8 substrate: When co-administering this drug with drugs metabolized by CYP2C8 (repaglinide, paclitaxel, etc.), caution should be exercised as the blood concentration of the combined drug may increase. When clopidogrel was coadministered with repaglinide in healthy adults, exposure to repaglinide increased, and in vitro tests confirmed that CYP2C8 was inhibited by the glucuronide metabolite of clopidogrel.
(7) In addition to the interaction studies with specific drugs mentioned above, patients who received this drug and participated in clinical trials (CAPRIE and CURE studies) have received various types of drugs in combination, such as diuretics, beta-blockers, angiotensin converting enzyme inhibitors, calcium channel blockers, cholesterol lowering agents, coronary vasodilators, hypoglycemic agents (including insulin), GPIIb/IIIa antagonists, antiepileptic drugs, and hormone replacement therapy. No significant adverse interactions were observed.
(8) There are no data on the concomitant administration of this drug with oral anticoagulants, oral antiplatelet agents that have not been studied, and long-term NSAIDs.
(9) Rosuvastatin: When this drug and 40 mg of rosuvastatin were administered together, the exposure of rosuvastatin increased. After administering 300 mg of clopidogrel, the AUC and Cmax of rosuvastatin increased by 2-fold and 1.3-fold, respectively. After repeated administration of 75 mg of clopidogrel, the AUC of rosuvastatin increased by 1.4-fold and Cmax was unaffected.

7. Administration to pregnant and lactating women
1) Pregnant women: In a reproductive toxicity test in which this drug was administered to rats and rabbits at doses of up to 500 and 300 mg/kg/day (65 and 78 times the human therapeutic dose, respectively), no abnormalities in fertility or fetal toxicity were found. No major birth defects or risks of miscarriage have been identified in the literature or post-marketing case reports regarding the use of clopidogrel in pregnancy. Myocardial infarction and stroke are emergency diseases, so treatment should not be withheld considering the potential impact on the fetus.
Use of clopidogrel during labor may increase the risk of bleeding in pregnant women. Neuraxial blockade should be avoided during clopidogrel use due to the risk of spinal hematoma. If possible, clopidogrel administration should be discontinued 5 to 7 days before delivery or neuraxial block.
2) Nursing mothers: In tests on rats, this drug and/or its metabolites were all secreted into the rats' milk. It is not known whether this drug is excreted in human milk. Since many drugs are secreted into breast milk in the human body and can cause serious adverse reactions in breast-feeding infants, the importance of the drug to the nursing mother must be taken into consideration when deciding whether to discontinue breastfeeding or drug administration.

8. Administration to children
Safety and efficacy in children have not been established.

9. Administration to elderly people
1) Plasma concentrations of major circulating metabolites were significantly higher in elderly patients (≥75 years old) compared to young, healthy volunteers, but there were no differences in platelet aggregation and bleeding time due to higher plasma concentrations.
2) Elderly people tend to have reduced physiological functions such as hematopoietic function, renal function, liver function, etc. and have low body weight, so they are prone to adverse reactions such as bleeding. Therefore, consider reducing the dose and administer carefully while observing the patient's condition.

10. Use in certain patients
1) Patients with impaired renal function
Upon repeated administration of 75 mg of this drug, plasma levels of major circulating metabolites were lower in patients with severe renal impairment (creatinine clearance 5 to 15 mL/min) compared to moderately impaired renal function (creatinine clearance 30 to 60 mL/min) or healthy patients. Although the inhibition of ADP-induced platelet aggregation was lower than that observed in healthy volunteers (25%), the prolongation of bleeding time was similar to that in healthy volunteers receiving 75 mg per day of ADP. No dose adjustment is necessary in patients with impaired renal function.
2) Gender
No significant differences in plasma concentrations of major circulating metabolites were observed between men and women. In a small trial comparing differences between men and women, less inhibition of ADP-induced platelet aggregation was observed in women, but no difference in prolonged bleeding time. Results of a large clinical trial (Clopidogrel versus Aspirin in Patients at Risk for Ischemic Disease; CAPRIE) showed that the incidence of clinical adverse events and laboratory abnormalities was similar between men and women.
3) Race: The prevalence of CYP2C19 alleles resulting in moderate or poor CYP2C19 metabolism differed depending on race/ethnicity.

11. Treatment in case of overdose
1) Overdosage of this drug may prolong the bleeding time and cause bleeding complications. An antidote to this drug has not yet been discovered. If rapid correction of prolonged bleeding time is necessary, platelet transfusion may be performed to reverse the effects of this drug.
2) One case of overdose of this drug was reported in a large-scale clinical trial. A 34-year-old woman took 1,050 mg of this drug (equivalent to 14 75 mg tablets) once, and there were no adverse reactions related to the medication. No specific treatment was administered, and the patient recovered without sequelae.
No adverse reactions occurred when 600 mg of this drug (equivalent to 8 75 mg tablets) was administered orally once to healthy volunteers. Bleeding time was prolonged by 1.7-fold, which is similar to that typically observed with a daily therapeutic dose of this drug (75 mg per day).
3) When administering this drug once orally, the lethal dose was 1,500 or 2,000 mg/kg in mice and rats, and 3,000 mg/kg was the lethal dose in baboons. Symptoms of acute toxicity were vomiting (in baboons), collapse, respiratory distress and gastrointestinal hemorrhage in all species.

12. Precautions for storage and handling
1) Keep out of reach of children.
2) Be careful because changing it into another container may cause an accident or is undesirable in terms of maintaining quality.

13. Others
1) No tumors occurred when this drug was administered to mice and rats for 78 and 104 weeks, respectively, at a dose of 77 mg/kg/day (plasma distribution more than 25 times the recommended human dose).
2) In four in vitro tests (Ames test, DNA-repair test on rat hepatocytes, gene mutation test on Chinese hamster fibroblasts, and metaphase chromosome analysis test on human lymphocytes) and one in vivo test (micronucleus test after oral administration to mice), genotoxicity due to this drug was not found.
3) This drug did not affect the fertility rate of male and female rats when administered orally at doses up to 400 mg/kg/day (52 times the recommended dose for humans based on mg/m2).
4) Results of reproductive toxicity test using animals: In the rat fertility and general reproductive toxicity test, a decrease in body weight of female offspring was observed when administering more than 100 mg/kg/day of this drug (5 to 8 weeks after birth), and in the teratogenicity test and perinatal/lactation test, a decrease in body weight of female offspring was observed when administering more than 400 mg/kg/day of this drug (5 to 7 weeks and 5 to 9 weeks of age).

5. How to save
Airtight container, stored at room temperature (1~30℃)

6. Packaging unit
30 tablets (10 tablets/Alu-Alu

7. Period of use
36 months from date of manufacture

Product Updates

Total 8items

No.Product NameDetailsDate of ChangeDownload
8Inhipla Tab.Precautions for use2023.03.09Inhipla Tablet Permission Change Order (Unification Adjustment).pdfFile under review
7Inhipla Tab.Precautions for use2018.08.28PDFŬ·ÎÇǵµ±×·¼È²»ê¿°+´ÜÀÏÁ¦(Á¤Á¦)+ÅëÀÏÁ¶Á¤(¾È).pdf
6Inhipla Tab.Inhipla Tablet (Precautions for use)2017.04.21HWP)Common changes (excluding export-only)_Clopidogrel sulfate (internally
5Inhipla Tab.Inhipla Tablet (Precautions for use)2017.04.05HWPClopidogrel sulfate single tablet unification adjustment plan.hwp
4Inhipla Tab.Inhipla Tablet (efficacy, dosage, directions for use...2012.12.31HWPInhiplajeong_Permission change order.hwp
3Inhipla Tab.Inhipla Tablet (Precautions for use)2011.10.28HWPInhipla Tablet (Precautions for use).hwp
2Inhipla Tab.Inhipla Tablet (efficacy, dosage, directions for use...2011.09.08HWPInhipla Tablet (effectiveness, dosage, precautions for use)
1Inhipla Tab.Inhipla Tablet (Precautions for use)2009.05.20HWPChange in Inhipla tablets (precautions for use) (2009.05.20).hwp